Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs
Journal of Veterinary Pharmacology and Therapeutics · 2022-07 · 45 (4) · 358-365
DOI: 10.1111/jvp.13056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, online erschienen am 21.04.2022. Verfasst von Hiroko Enomoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA. Hauptthemen laut MEDLINE: Buprenorphine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Center for chemical Toxicology Research and Pharmacokinetics of North Carolina State University, Zoetis generously provided the Simbadol™ used in this study., Zoetis.
Abstract (Originalsprache)
Effective management of pain in animals is of critical importance but options are limited for treating acute pain in dogs on an outpatient basis. The objective of this study was to compare the plasma concentrations and pharmacokinetics of a concentrated solution of buprenorphine, 1.8 mg/ml (Simbadol™) administered intravenously, intranasally, and via the oral transmucosal (OTM) route in healthy male dogs. Five healthy castrated adult male Beagle‐cross dogs were included in this randomized blocked crossover study. The dogs received 0.03 mg/kg body weight buprenorphine intravenously, intranasally, or via the OTM route, with a minimum 72‐h washout period between treatments. Blood samples were collected at multiple intervals up to 24 h post administration and buprenorphine plasma concentrations were determined by liquid chromatography tandem mass spectrometry. Non‐compartmental pharmacokinetic analysis revealed that the area under the curve of intravenous, intranasal, and OTM routes were 28.0 (15.1–41.3) h × ng/ml, 16.1 (3.4–28.7) h × ng/ml and 10.8 (8.8–11.8) h × ng/ml, respectively. The bioavailability of intranasal and OTM routes were 57.5 (22.7–93.7)% and 41.1 (25.5–69.4)%, respectively. Intranasal and OTM routes of administration of concentrated buprenorphine in dogs may allow for the provision of analgesic care at home.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Comparative Medicine Institute, North Carolina State University, Raleigh, North Carolina, USA.
- Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, North Carolina, USA.
ORCID-Profile: Hiroko Enomoto, Kristen M Messenger
Förderung
- Center for chemical Toxicology Research and Pharmacokinetics of North Carolina State University
- Zoetis generously provided the Simbadol™ used in this study.
- Zoetis
Zitieren
APA
Enomoto, H., Love, L., Madsen, M., Wallace, A., & Messenger, K. M. (2022). Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs. Journal of Veterinary Pharmacology and Therapeutics, 45(4), 358-365. https://doi.org/10.1111/jvp.13056
Vancouver
Enomoto H, Love L, Madsen M, Wallace A, Messenger KM. Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs. Journal of Veterinary Pharmacology and Therapeutics. 2022;45(4):358-365. doi:10.1111/jvp.13056
BibTeX
@article{Enomoto2022,
author = {Enomoto, Hiroko and Love, Lydia and Madsen, Melanie and Wallace, Amber and Messenger, Kristen M},
title = {Pharmacokinetics of intravenous, oral transmucosal, and intranasal buprenorphine in healthy male dogs},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2022},
volume = {45},
number = {4},
pages = {358--365},
doi = {10.1111/jvp.13056}
}
EUVIMED